To further validate our hypothesis that MEKi-mediated potentiation of ERα is important in mediating the synergy and anti-tumor effect of combined MEKi and fulvestrant, we evaluated the expression of ER-responsive genes after treatment with MEKi or fulvestrant, or the combination of both (Fig. 2B & C). This evidence concerns the gene ESR1 and neoplasm.